Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Theseus Pharmaceuticals
Cambridge, Massachusetts, United Statestheseusrx.com ↗
- Ownership
- Public · THRX
- Employees
- ~38
- Development stage
- Other
01
Overview
Theseus Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing next-generation small molecule pan-varient tyrosine kinase inhibitors to overcome resistance mutations in key oncogenes. Its lead program, THE‑630, targeted all classes of activating and resistance mutations in the KIT receptor for GIST and was in Phase I/II trials. Additional programs included a fourth-generation EGFR inhibitor for NSCLC and a BCR–ABL inhibitor for CML and Ph+ ALL. The company was acquired by Concentra Biosciences in February 2024.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeTyrosine kinase inhibitor (TKI)
- Industry
- Biotech
Beyond the preview
Go deeper on Theseus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theseus Pharmaceuticals.